Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCWB HCW Biologics	$4.43 -4.5%	$4.67	$3.55 ▼ $100.80	$6.36M	0.66	380,801 shs	9,344 shs
LIAN LianBio	$0.05	$0.27	$0.27 ▼ $4.99	$5.43M	0.23	1.04 million shs	203 shs
PPBT Purple Biotech	$2.22 +0.7%	$2.43	$2.00 ▼ $13.95	$5.74M	0.49	91,630 shs	15,048 shs
PTIX Atrinsic	$2.70 -3.6%	$3.39	$2.35 ▼ $15.54	$1.59M	0.34	945,108 shs	32,486 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCWB HCW Biologics	+0.43%	+10.48%	+6.67%	-53.83%	-80.63%
LIAN LianBio	0.00%	-7.52%	-88.23%	-74.27%	-84.58%
PPBT Purple Biotech	+3.29%	-0.45%	-10.71%	-2.22%	+219,999,900.00%
PTIX Atrinsic	-1.06%	+4.09%	-24.12%	-20.23%	-68.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HCWB HCW Biologics	3.1714 of 5 stars	3.5	5.0	0.0	0.0	3.3	1.7	0.0
LIAN LianBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PPBT Purple Biotech	2.4797 of 5 stars	3.5	5.0	0.0	0.0	1.2	0.0	0.6
PTIX Atrinsic	0.5485 of 5 stars	0.0	5.0	0.0	0.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCWB HCW Biologics	3.00	Buy	$35.00	690.07% Upside
LIAN LianBio	0.00	N/A	N/A	N/A
PPBT Purple Biotech	3.00	Buy	$33.00	1,389.84% Upside
PTIX Atrinsic	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PTIX, HCWB, PPBT, and LIAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/29/2025	HCWB HCW Biologics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$120.00 ➝ $35.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCWB HCW Biologics	$2.57M	2.48	N/A	N/A	($6.08) per share	-0.73
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
PPBT Purple Biotech	N/A	N/A	N/A	N/A	$12.73 per share	N/A
PTIX Atrinsic	N/A	N/A	N/A	N/A	$1.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCWB HCW Biologics	-$30.02M	-$23.25	N/A	∞	N/A	-1,712.94%	N/A	-90.09%	8/13/2025 (Estimated)
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
PPBT Purple Biotech	-$7.24M	-$0.42	N/A	N/A	N/A	N/A	-14.00%	-12.52%	8/15/2025 (Estimated)
PTIX Atrinsic	-$5.53M	-$13.11	N/A	∞	N/A	N/A	-860.52%	-354.19%	8/13/2025 (Estimated)

Latest PTIX, HCWB, PPBT, and LIAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	N/A	PPBT Purple Biotech	-$0.21	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	PPBT Purple Biotech	-$0.21	-$0.40	-$0.19	-$0.40	N/A	N/A
5/21/2025	Q1 2025	PPBT Purple Biotech	N/A	-$0.17	N/A	-$0.17	N/A	N/A
5/15/2025	Q1 2025	HCWB HCW Biologics	N/A	-$0.05	N/A	-$0.05	N/A	N/A
5/13/2025	Q1 2025	PTIX Atrinsic	N/A	-$2.75	N/A	-$2.75	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCWB HCW Biologics	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
PPBT Purple Biotech	N/A	N/A	N/A	N/A	N/A
PTIX Atrinsic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCWB HCW Biologics	N/A	0.07	0.07
LIAN LianBio	N/A	10.06	10.06
PPBT Purple Biotech	N/A	2.88	2.88
PTIX Atrinsic	N/A	0.86	0.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCWB HCW Biologics	2.96%
LIAN LianBio	74.85%
PPBT Purple Biotech	9.64%
PTIX Atrinsic	7.97%

Insider Ownership

Company	Insider Ownership
HCWB HCW Biologics	42.70%
LIAN LianBio	7.59%
PPBT Purple Biotech	2.98%
PTIX Atrinsic	35.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCWB HCW Biologics	40	1.44 million	825,000	Not Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
PPBT Purple Biotech	20	2.59 million	2.51 million	Optionable
PTIX Atrinsic	2	590,000	383,000	Not Optionable

PTIX, HCWB, PPBT, and LIAN Headlines

Recent News About These Companies

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates

July 30, 2025 | prismmediawire.comP

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates

July 30, 2025 | globenewswire.com

Protagenic Therapeutics, Inc. (PTIX) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail Frenzy

May 29, 2025 | msn.com

Protagenic Therapeutics swaps warrants for shares

May 21, 2025 | uk.investing.com

Protagenic Therapeutics and Phytanix merge in all stock deal

May 21, 2025 | thepharmaletter.comT

Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity

May 21, 2025 | accessnewswire.comA

Protagenic Therapeutics Shares Double After Buyout Offer From Phytanix Bio

May 20, 2025 | marketwatch.com

Protagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical company

May 20, 2025 | in.investing.com

Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely Bullish

May 20, 2025 | msn.com

Protagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma Firm

May 20, 2025 | msn.com

PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders

May 19, 2025 | businesswire.com

Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders

May 19, 2025 | accessnewswire.comA

Protagenic Therapeutics Inc.

May 9, 2025 | barrons.com

Protagenic Therapeutics, Inc.: Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split

April 29, 2025 | finanznachrichten.de

Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split

April 29, 2025 | accessnewswire.comA

Protagenic Therapeutics adjusts stock option prices

February 26, 2025 | uk.investing.com

PTIX stock touches 52-week low at $0.25 amid sharp annual decline

February 11, 2025 | msn.com

Avalon Holdings (AMEX:AWX) Stock Quotes, Forecast and News Summary

January 30, 2025 | benzinga.com

Performance Tech stock hits 52-week low at $0.4

January 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX, HCWB, PPBT, and LIAN Company Descriptions

HCW Biologics NASDAQ:HCWB

$4.43 -0.21 (-4.53%)

As of 03:17 PM Eastern

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

LianBio NASDAQ:LIAN

$0.05 0.00 (0.00%)

As of 08/11/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Purple Biotech NASDAQ:PPBT

$2.22 +0.02 (+0.68%)

As of 03:15 PM Eastern

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Atrinsic NASDAQ:PTIX

$2.70 -0.10 (-3.57%)

As of 03:06 PM Eastern

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time